Kristen V. Brown, a staff writer for The Atlantic specializing in health and genetic data, dives into the tumultuous journey of 23andMe. The conversation reveals the looming risks of genetic data privacy and the implications of possible data breaches. Kristen discusses the company’s drastic decline from its promising start, the waning interest in DNA testing, and the urgent need for clearer consumer protections. She also highlights the ethical dilemmas surrounding data ownership and the future challenges posed by genetic technology.
23andMe's decline reflects broader industry struggles, primarily due to privacy concerns and a loss of consumer trust in genetic data management.
The potential misuse of genetic data raises urgent privacy issues, highlighting the need for stronger regulations to protect users' sensitive information.
Deep dives
The Journey of DNA Testing
The fascination with DNA testing has surged, with many, including Kristen V. Brown, taking multiple tests to uncover their ancestry and health information. Despite the personal connections these tests can forge, results can sometimes lead to unexpected family revelations, as seen in Brown's experience discovering Italian ancestry instead of the expected Syrian lineage. Many individuals, however, find the health insights provided are not as actionable or illuminating as anticipated, leading to question the value of the information received. This has contributed to a decline in enthusiasm for DNA testing, despite its initial popularity promoted by celebrities and cultural phenomena.
Challenges Facing 23andMe
23andMe has recently faced significant challenges, including a plummeting stock price and risk of delisting from the stock market, indicative of broader struggles within the industry. The company has experienced an erosion of trust, partially due to privacy concerns from past data breaches and general unease about how genetic data might be used, especially following high-profile criminal cases. Additionally, the FDA's previous interventions and the slow pace of profitable drug development further complicate 23andMe's operational viability. These factors have combined to create a landscape where consumer interest wanes and the once-promising outlook for personal genomics appears increasingly fragile.
The Future of Genetic Data Privacy
The handling and potential sale of genetic data raise complex privacy concerns, particularly as companies like 23andMe may categorize this information as assets. If the company were sold, customer data could be transferred under new terms that might not be favorable to users, leading to potential misuse. Furthermore, even past breaches reveal the vulnerability of genetic data, exposing information that can be uniquely sensitive and revealing about individuals' identities and histories. Current regulatory protections, such as GINA, provide limited safeguards, especially with the evolving landscape of genetic information, underscoring the need for stronger regulations to protect consumer privacy.
Want more What Next TBD? Subscribe to Slate Plus to access ad-free listening to the whole What Next family and all your favorite Slate podcasts. Subscribe today on Apple Podcasts by clicking “Try Free” at the top of our show page. Sign up now at slate.com/whatnextplus to get access wherever you listen.
Podcast production by Evan Campbell, Patrick Fort, and Cheyna Roth.